- Home
- INBX vs IVA Comparison
INBX vs IVA Comparison
Compare INBX & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- IVA
- Stock Information
- Founded
- INBX 2010
- IVA 2011
- Country
- INBX United States
- IVA France
- Employees
- INBX N/A
- IVA N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- INBX Health Care
- IVA Health Care
- Exchange
- INBX Nasdaq
- IVA Nasdaq
- Market Cap
- INBX 168.1M
- IVA 359.6M
- IPO Year
- INBX 2020
- IVA 2020
- Fundamental
- Price
- INBX $11.18
- IVA $3.62
- Analyst Decision
- INBX Hold
- IVA Strong Buy
- Analyst Count
- INBX 1
- IVA 4
- Target Price
- INBX N/A
- IVA $10.50
- AVG Volume (30 Days)
- INBX 97.5K
- IVA 19.2K
- Earning Date
- INBX 05-20-2025
- IVA 03-26-2025
- Dividend Yield
- INBX 7.56%
- IVA N/A
- EPS Growth
- INBX N/A
- IVA N/A
- EPS
- INBX 112.62
- IVA N/A
- Revenue
- INBX $200,000.00
- IVA $14,591,573.00
- Revenue This Year
- INBX N/A
- IVA $15.38
- Revenue Next Year
- INBX N/A
- IVA $24.22
- P/E Ratio
- INBX $0.10
- IVA N/A
- Revenue Growth
- INBX N/A
- IVA N/A
- 52 Week Low
- INBX $10.80
- IVA $1.53
- 52 Week High
- INBX $18.95
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- INBX 38.27
- IVA 56.12
- Support Level
- INBX $10.90
- IVA $3.40
- Resistance Level
- INBX $12.60
- IVA $3.77
- Average True Range (ATR)
- INBX 0.86
- IVA 0.25
- MACD
- INBX -0.03
- IVA -0.04
- Stochastic Oscillator
- INBX 14.28
- IVA 43.79
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.